Europe Set To Get Live Pandemic Bird Flu Vaccine Protection
This article was originally published in Scrip
Executive Summary
Europe looks set to get its first pandemic live attenuated influenza vaccine for fighting H5N1-strain bird flu after EMA's top advisory panel backed use of AstraZeneca PLC's version in an officially declared pandemic situation in children and adolescents.
You may also be interested in...
CDC Loses Faith In AstraZeneca's Nasal Spray Flu Vaccine
The US Centers for Disease Control and Prevention has decided not to recommend AstraZeneca PLC's nasal spray flu vaccine FluMist Quadrivalent (known as Fluenz Tetra in Europe) for the upcoming flu season owing to lack of efficacy. AstraZeneca said it would take an $80m write-down on stocks in the second quarter as a result.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.